Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 25Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14sargramostim 12Radiotherapy, Intensity-Modulated 12Radiotherapy, Conformal 12Sirolimus 10Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8pembrolizumab 8Thalidomide 8Sorafenib 8Radiosurgery 8Gefitinib 8motexafin gadolinium 7aldesleukin 7Procarbazine 7Gene Expression Profiling 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × sapanisertib × Sarcoma × Clear all
NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡